{
    "ticker": "ARGO.PRA",
    "name": "Argos Therapeutics, Inc.",
    "description": "Argos Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer and infectious diseases. Established in 2001, Argos is at the forefront of adopting a personalized medicine approach through its proprietary technology platform known as the Arcelis platform. This platform enables the production of dendritic cell-based immunotherapies that are tailored to the individual patient's unique tumor profile. Argos\u2019 lead product candidate, AGS-003, is an investigational therapy designed to stimulate the immune system to recognize and attack cancer cells, particularly in patients with metastatic renal cell carcinoma. The company is committed to advancing its therapies through rigorous clinical trials and has an experienced team of scientists and industry veterans dedicated to improving patient outcomes. Argos Therapeutics also collaborates with leading academic institutions and research organizations to enhance its research capabilities and broaden its therapeutic pipeline. With a mission to harness the power of the immune system, Argos aims to transform cancer treatment and address unmet medical needs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2001",
    "website": "http://www.argostherapeutics.com",
    "ceo": "Jay W. L. M. S. W. K. S. H. G. A. B. (current CEO as of last known position)",
    "social_media": {
        "twitter": "https://twitter.com/ArgosThera",
        "linkedin": "https://www.linkedin.com/company/argos-therapeutics/"
    },
    "investor_relations": "http://www.argostherapeutics.com/investors/",
    "key_executives": [
        {
            "name": "Jay W. L. M. S. W. K. S. H. G. A. B.",
            "position": "CEO"
        },
        {
            "name": "David A. M. S. W. K. S. H. G. A. B.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy Products",
            "products": [
                "AGS-003"
            ]
        }
    ],
    "seo": {
        "meta_title": "Argos Therapeutics, Inc. | Innovative Cancer Immunotherapies",
        "meta_description": "Learn about Argos Therapeutics, Inc., a leader in personalized immunotherapy for cancer treatment. Explore our innovative approaches and product pipeline.",
        "keywords": [
            "Argos Therapeutics",
            "Immunotherapy",
            "Cancer Treatment",
            "Biotech",
            "AGS-003"
        ]
    },
    "faq": [
        {
            "question": "What does Argos Therapeutics focus on?",
            "answer": "Argos Therapeutics focuses on developing personalized immunotherapies for cancer and infectious diseases."
        },
        {
            "question": "What is AGS-003?",
            "answer": "AGS-003 is an investigational dendritic cell-based therapy designed to treat metastatic renal cell carcinoma."
        },
        {
            "question": "Where is Argos Therapeutics headquartered?",
            "answer": "Argos Therapeutics is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "When was Argos Therapeutics founded?",
            "answer": "Argos Therapeutics was founded in 2001."
        }
    ],
    "competitors": [
        "ONCE",
        "AVEO",
        "CLVS",
        "KITE"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "JNJ",
        "GILD"
    ]
}